We present a comprehensive, up-to-date review of host-directed therapeutics (HDTs) to improve clinical outcome in tuberculosis (TB) disease, summarizing all compounds, primarily repurposed drugs, tested in human clinical trials. Where available, results from each phase of these investigations are discussed.
- C. Young
- G. Walzl
- N. Du Plessis